Navigation Links
Saline Wash May Ease Shoulder Tendonitis
Date:11/28/2007

Study supports effectiveness of the ultrasound-guided technique

WEDNESDAY, Nov. 28 (HealthDay News) -- A new minimally invasive procedure is a quick, inexpensive way to treat tendonitis in the shoulder, Italian researchers report.

The researchers used ultrasound-guided percutaneous (through the skin) therapy to treat the shoulders of more than 2,000 people (average age 42) with calcific tendonitis, characterized by the formation of small calcium deposits within the tendons of the rotator cuff. These deposits can cause pain and restrict mobility.

Ultrasound-guided percutaneous therapy is a 10-minute procedure in which a radiologist, guided by ultrasound, injects a saline solution into the rotator cuff to wash the area and break up the calcium. A second needle is then used to remove the calcium residue. Patient recovery time is about an hour.

In 71.7 percent of patients, the calcification was fully removed in one treatment, resulting in improved mobility and pain reduction. In 23.6 percent of patients, a second treatment was required because of the presence of more than one calcification. In 3.8 percent of patients, the calcification had moved or dissolved before treatment. In 0.9 percent of patients, there was no easing of symptoms, due to the presence of a tendon tear.

The findings were to be presented Wednesday at the annual meeting of the Radiological Society of North America in Chicago.

"This is a quick, successful and inexpensive therapy for tendon calcifications. It provides significant and long-lasting reduction of symptoms," Dr. Luca M. Sconfienza, of the department of radiology at A.O. Ospedale Santa Corona in Pietre Ligure, and the department of experimental medicine at the University of Genova, said in a prepared statement.

While only a few institutions currently offer this therapy, it could be performed in any hospital or clinic that has ultrasound equipment with a superficial probe, S
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Saline Reduces Mortality for Brain Injury Patients
2. Saline Irrigation Eases Chronic Nasal Symptoms
3. New treatment effective for patients with shoulder pain
4. A New Study Links High Volume Pain Pumps with the Devastating and Painful Loss of Cartilage Following Arthroscopic Shoulder Surgery
5. How pitching changes little leaguers shoulders
6. Study Author Urges Peers to Stop Using Pain Pumps in the Shoulder Joint as Seasonal Surge in Use Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Frost & Sullivan to Hold Web Conference on Integrated Hospital Pharmacy Information Systems - How to Maneuver towards Growth Potential 2Health News:OrderOnlineDrugs.com Makes Ordering Drugs Online Safe and Affordable 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 2Health News:Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies 3Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 2Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 3Health News:Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss 4Health News:Buffalo Personal Injury Lawyers Cellino & Barnes Donate $1M to UB School of Law, Appear on Cover of School's Philanthropy Magazine 2
Breaking Medicine Technology:$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 1High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 2High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 3As Greenland melts 10423 1As Greenland melts 10423 2Research with wood ducks earns graduate student 2 national awards 10420 1
Other Medicine Technology:Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 2Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 3Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV) 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 2Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 3Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 4Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 5Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 6Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 7Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 8Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference 9